Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959246 | 0.96 | MAPT (0.57) | MAPTPKMPOLBSMN1; SMN2KDM4E | |
| SCHEMBL1957549 | 0.91 | MAPT (0.50) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL2481693 | 0.91 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1700080 | 0.80 | MAPT (0.67) | MAPTPKMPOLBSMN1; SMN2KDM4E | |
| SCHEMBL1960223 | 0.80 | KDM4E (0.47) | MAPTPKMPOLBSMN1; SMN2KDM4E | |
| SCHEMBL21751695 | 0.79 | MAPT (0.59) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1957948 | 0.78 | MAPT (0.67) | MAPTPKMPOLBSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL21751590 | 0.78 | MAPT (0.58) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1699958 | 0.78 | MAPT (0.72) | MAPTPKMPOLBSMN1; SMN2KDM4E | |
| SCHEMBL30468003 | 0.78 | MAPT (0.72) | MAPTPKMPOLBSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |